Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 14/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 0.72 |
| ▸ | RAB9A | P51151 | 6/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4345510 | 0.85 | RAB9A (0.75) | GRIK1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL1462337 | 0.81 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL107421 | 0.80 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2KMT2AMAPT | |
| SCHEMBL4355476 | 0.79 | NPC1 (0.73) | GRIK1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL3961840 | 0.78 | GRIK1 (1.00) | GRIK1NPC1RAB9AKMT2AMAPT | |
| SCHEMBL3958601 | 0.78 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL23831439 | 0.77 | GRIK1 (0.80) | GRIK1GRIK2 | |
| SCHEMBL3957527 | 0.77 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL3455487 | 0.77 | RAB9A (0.85) | GRIK1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL3962344 | 0.77 | GRIK1 (1.00) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069255-A1 | Novel aryl ureido benzoic acid derivatives and their use | NEUROSEARCH (DK) | 2006-03-30 | — | — | US | claimed |
| US-7521480-B2 | Aryl ureido benzoic acid derivatives and their use | NEUROSEARCH (DK) | 2009-04-21 | — | — | US | disclosed |
| US-20060069255-A1 | Novel aryl ureido benzoic acid derivatives and their use | NEUROSEARCH (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1565429-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004046090-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069255-A1 | Novel aryl ureido benzoic acid derivatives and their use | GABRA5, GRIK5, GRM5 | GRIK1 24/4885NPC1 2512/4885RAB9A 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.